Key Stats for Novo Nordisk Stock
- Current Price: $44.56
- Target Price (Mid): ~$68
- Street Target: ~$47
- Potential Total Return: ~53%
- Annualized IRR: ~10% / year
Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free) >>>
What Happened?
Novo Nordisk (NVO) will put its whole strategy on the table in London on September 21, and it does so from a position almost no one expected a year ago: near the bottom of its 52-week range. The stock closed at $44.56 on September 9, closer to its $35.12 low than to the $64.16 high it touched twelve months back. What makes the setup strange is that the business underneath has started working again. Obesity sales grew 16% last quarter, the Wegovy pill is the strongest GLP-1 launch by volume the company has ever run, and management raised full-year guidance for the second time this year, though to a still-cautious 0% to -6% adjusted sales growth at constant currencies.
On September 7, Novo reported a successful pediatric obesity trial and, the same day, disclosed a second pipeline failure, and the shares slid over the sessions that followed, closing near $44.56 by September 9. Closing the gap between a franchise that is executing and a stock that will not respond is what Capital Markets Day has to do.
The Quarter Was Good and the Stock Shrugged
Novo delivered a clean beat in the second quarter, reported August 4. Revenue came in at DKK 78,488 million against a Street estimate of DKK 71,535 million, a 9.72% beat, and adjusted earnings per share of 6.18 topped the 4.98 consensus by 24%, per TIKR’s earnings data. Adjusted sales grew 7% at constant exchange rates and adjusted operating profit rose 11%.
Investors have been trained by a brutal 2026 to distrust good prints, and the reasons are on the record: a max drawdown of 44.84% on March 30, repeated pricing scares, and steady U.S. share loss to Eli Lilly. The quarter did not erase that memory. The oral launch is the clearest evidence it should start to. EVP of U.S. Operations Jamey Millar called the Wegovy pill “the strongest ever GLP-1 launch by volume,” now past five million total prescriptions with the latest million added in four weeks, and holding around 90% of the U.S. oral obesity market against an April competitor.
See historical and forward estimates for Novo Nordisk stock (It’s free!) >>>
The Pipeline Keeps Testing Investor Patience
On September 7, Novo halted two more cardiovascular trials of ziltivekimab, HERMES and ATHENA, after a data monitoring committee found them unlikely to succeed. That followed the July failure of the ZEUS outcomes trial, where the drug lowered inflammation markers but did not cut major adverse cardiovascular events, with a hazard ratio of 0.99. Novo has been reported to be taking a non-cash impairment charge tied to the program in the third quarter, though the company has not detailed the figure. The setback landed the same day as a win: the STEP Young pediatric trial met its primary endpoint, with 40.4% of children aged 6 to under 12 no longer classified as obese after 68 weeks. The stock still fell, because the market weighed the CV failure more heavily than the pediatric success.
Chief Scientific Officer Martin Lange framed the cardiovascular program as a bet Novo always knew was risky, telling analysts it had carried a probability of technical success of around 50% or less. He is right that one failed hypothesis does not sink a pipeline this broad, and the surviving ARTEMIS heart-attack trial still reads out in the first half of 2027. Yet the read-across is real: investors buying Novo for diversification beyond obesity have watched that diversification narrow twice in two months.
Why September 21 Is the Real Catalyst
NVO trades at an NTM P/E of 12.74x and an NTM EV/EBITDA of 9.54x, per TIKR’s Multiples data, against an LTM gross margin of 82.0% and a return on equity of 59.8%. For peer context from TIKR’s Competitors page, Eli Lilly trades at 27.56x NTM P/E, Roche at 16.38x, and Novartis at 14.63x. Novo is priced below every major peer despite top-of-group margins, so the market is pricing a growth problem, not a quality problem. Whether that discount is deserved depends on the U.S. pricing path, which is exactly what management has spent all year trying to answer.
What Novo needs to supply on September 21 is a framework for 2027, and the Q2 call showed why it matters. CFO Karsten Knudsen walked analysts through the math: the second half absorbs the loss of exclusivity for semaglutide in markets like Canada and Brazil, plus a tough comparison against roughly DKK 5 billion of favorable one-time rebate effects booked in late 2025. The rebate comparison does not repeat next year, but the patent erosion annualizes into it. Management declined to guide 2027 and deferred to February, which is the void the strategy day can start to fill.
The international pill data is the strongest card management holds going in. EVP of International Operations Emil Larsen told analysts that three weeks into the U.K. launch, Novo estimated “around 300,000 patients have started on the Wegovy pill,” lifting the company’s U.K. obesity market share from about 30% to 45% on IQVIA sell-in data, with only 1.6 million of an estimated 20 million obese U.K. adults currently treated. Germany launches in September, with China behind it. A believable link between that rollout and a revenue reacceleration gives the stock room to re-rate. Absent one, the discount holds. A DKK 15 billion buyback, which had retired more than 32 million B shares by early September per company disclosures, puts a floor under the wait.
See how Novo Nordisk performs against its peers in TIKR (It’s free!) >>>
TIKR Advanced Model Analysis
- Current Price: $44.56
- Target Price (Mid): ~$68
- Potential Total Return: ~53%
- Annualized IRR: ~10% / year
See analysts’ growth forecasts and price targets for Novo Nordisk stock (It’s free!) >>>
TIKR’s mid-case scenario, realized at December 31, 2030, targets approximately $68 for NVO, a potential total return of around 53% and an annualized IRR of about 10% from today’s price. Two revenue drivers carry the roughly 6% CAGR: the international oral Wegovy rollout as markets like the U.K. and Germany scale, and a CagriSema contribution once its U.S. obesity decision arrives at the end of 2026. The margin driver is operating leverage on high-conversion reimbursed volume, holding a mid-case net income margin near 32%. The primary risk is U.S. price erosion outpacing volume. Upside: a clean international rollout restores mid-single-digit growth and the multiple re-rates toward peers. Downside: pricing pressure and Lilly’s share gains swallow the volume story.
Conclusion
September 21 sets the near-term direction. The Street mean target sits at roughly $47, barely above the current price, and the analyst base is openly split, with Deutsche Bank and Citi at Sell and Berenberg, Argus, and JPMorgan at Hold or Neutral. That absence of conviction is the opportunity: a strategy day that puts real numbers on the international pill rollout and a U.S. price floor could force a re-rate. Good would be a credible path back to mid-single-digit revenue growth in 2027, the guidance management withheld in August. Bad would be another quarter of wait-and-see with no timeline for when pricing stabilizes.
See what stocks billionaire investors are buying so you can follow the smart money with TIKR.
Should You Invest in Novo Nordisk?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up Novo Nordisk, and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track Novo Nordisk alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Analyze Novo Nordisk on TIKR Free →
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
